Essen

• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma Ended
  2024-511996-13-00 5 2022-05-11 Previously untreated, unresectable, or metastatic melanoma
• N/A Ended
  2024-515090-96-00 11 2022-05-10 Thyroid Eye Disease
• Phase 2 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ended
  2023-504825-38-00 4 2022-04-15 Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
• Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of … Ended
  2024-511263-28-00 6 2022-04-08 Hypercholesterolemia
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Subjects 2 Years and Older Ended
  2024-515606-90-00 5 2022-04-01 Cystic Fibrosis
• Brightline-1: A study to compare brigimadlin (BI 907828) with doxorubicin in people with a type of cancer called dedifferentiated liposarcom … Ended
  2024-511361-11-00 10 2022-03-25 Advanced dedifferentiated liposarcoma
• Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections … Ended
  2023-510088-37-00 5 2022-03-15 Acyclovir-resistant mucocutaneous HSV infections in immunocompromised
• Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis Ended
  2023-506004-93-00 4 2022-03-01 Ulcerative Colitis (UC)
• A multi-center interventional study to assess pharmacokinetics, effectiveness and tolerability of prolonged-release Tacrolimus after Paediat … Ended
  2024-516608-40-00 10 2022-02-23 Caucasian paediatric kidney transplant recipients
• Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumours Ended
  2024-511071-16-00 3 2022-02-10 Solid Tumours
• GRAPPA Ended
  2023-510441-24-00 5 2022-01-28 Graft Vs Host Disease Peripheral Blood Stem Cell Transplantation AML M
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Ended
  2023-507093-40-00 4 2022-01-27 Chronic Obstructive Pulmonary Disease (COPD)
• An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasth … Ended
  2024-510932-36-00 5 2021-12-21 Generalized Myasthenia Gravis (gMG)
• Escalated single Platelet Inhibition for one month plus Direct oral anticoagulation in patients with Atrial fibrillation and acUte coRonary … Ended
  2024-512727-36-00 6 2021-12-21 Patients with atrial fibrillation and ST-segment elevation myocardial
• Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III … Ended
  2023-507688-20-00 5 2021-12-03 Participants with completely resected Stage III or Stage IV melanoma
• Phase II Study of efti plus pembrolizumab combination therapy for head and neck cancer (HNSCC). Ended
  2024-510762-16-00 4 2021-11-30 Metastatic head and neck squamous cell carcinoma (HNSCC)
• FINISHER – Fight INflammation to Improve outcome after aneurysmal Subarachnoid HEmorRhage Ended
  2024-512314-17-00 5 2021-11-24 Aneurysmal Subarachnoid Hemorrhage (SAH)
• The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic … Ended
  2024-517251-12-00 5 2021-11-02 Recurrent or metastatic head and neck squamous cell carcinoma
• Study to Evaluate the Long-Term Efficacy and Safety of the Investigational Drug LIB003 for the Reduction of Cholesterol in Patients with Hom … Ended
  2023-510057-41-00 5 2021-10-06 Patients With Homozygous and Heterozygous Familial Hypercholesterolemi
• An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed … Ended
  2024-512717-41-00 4 2021-10-01 Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
• A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical Cancer Ended
  2023-503813-31-01 5 2021-09-17 Second- or Third-Line Recurrent or Metastatic Cervical Cancer
• Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Ended
  2024-511728-15-00 7 2021-08-26 Solid tumors
• Study to investigate the efficacy and safety of allo-APZ2-CVU on wound healing of therapy-resistant chronic venous ulcer (CVU) Ended
  2023-510162-27-00 4 2021-08-18 Chronic venous ulcers (CVU)
• Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended
  2023-507096-21-00 5 2021-08-16 Chronic or Episodic Migraine (Migraine without aura, migraine with aur

Showing 889–912 of 965 trials